GILD Stock DD Gilead Sciences, Inc. 09/11/2014 22:31:16

New Post Public Reply Private Reply Replies (0) Message Board
Rosner
GILD Gilead Sciences, Inc. $GILD Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=GILD&...mp;yt0=Go!

Last Updated: 09/11/2014 22:31:11

Current Price and Quotes
Last Price 106.39
Previous Close 108.22 Open 108.00
Daily Range 105.80 - 108.49 52wk Range 58.81 - 110.64
Volume 10,471,049 Dividend N/A
Average Vol (30d) 13,713,068 Yield N/A




Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 11,201,688 9,702,517 8,385,385 7,949,420
Cost of Revenue 2,858,502 2,471,363 2,124,410 1,869,876
Gross Profit 8,343,186 7,231,154 6,260,975 6,079,544
Operating Expenses

Research and Development 2,119,756 1,759,945 1,229,151 1,072,930
Sales, General and Admin. 1,699,431 1,461,034 1,241,983 1,044,392
Non-Recurring Items - - - -
Other - - - -
Operating Income 4,523,999 4,010,175 3,789,841 3,962,222
Income From Continuing Operations

Add'l Income/Expense Items (8,886) (37,279) 66,581 60,287
Earnings Before Interest and Tax 4,515,113 3,972,896 3,856,422 4,022,509
Interest Expense 306,894 360,916 205,418 108,961
Earnings Before Tax 4,208,219 3,611,980 3,651,004 3,913,548
Income Tax 1,150,933 1,038,381 861,945 1,023,799
Minority Interest (17,522) (17,967) (14,578) (11,508)
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 3,074,808 2,591,566 2,803,637 2,901,257
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 3,074,808 2,591,566 2,803,637 2,901,257
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 3,074,808 2,591,566 2,803,637 2,901,257

Recent News


GILD Gilead Sciences, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/GILD/quote
Stock Chart http://www.otcmarkets.com/stock/GILD/chart
Company Info http://www.otcmarkets.com/stock/GILD/company-info
Recent News http://www.otcmarkets.com/stock/GILD/news
Financials http://www.otcmarkets.com/stock/GILD/financials
Filings and Disclosure http://www.otcmarkets.com/stock/GILD/filings
Short Sales http://www.otcmarkets.com/stock/GILD/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/GILD/insider-transactions
Research Reports http://www.otcmarkets.com/stock/GILD/research
Summary http://finance.yahoo.com/q?s=GILD
Historical Prices http://finance.yahoo.com/q/hp?s=GILD+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=GILD
Basic Chart http://finance.yahoo.com/q/bc?s=GILD+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=GILD+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=GILD+Headlines
Press Releases http://finance.yahoo.com/q/p?s=GILD+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=GILD+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=GILD+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=GILD+Industry
Major Holders http://finance.yahoo.com/q/mh?s=GILD+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=GILD+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=GILD+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=GILD
Balance Sheet http://finance.yahoo.com/q/bs?s=GILD
Cash Flow http://finance.yahoo.com/q/cf?s=GILD+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/GILD
Market Watch http://www.marketwatch.com/investing/stock/GILD
Bloomberg http://www.bloomberg.com/quote/GILD:US
Morningstar http://quotes.morningstar.com/stock/s?t=GILD
Bussinessweek http://investing.businessweek.com/research/st...icker=GILD
Barchart http://www.barchart.com/quotes/stocks/GILD
OTC Short Report http://otcshortreport.com/index.php?index=GILD
Investopedia http://www.investopedia.com/markets/stocks/GILD/?wa=0
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading